CA2381699A1 - Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators - Google Patents

Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators Download PDF

Info

Publication number
CA2381699A1
CA2381699A1 CA002381699A CA2381699A CA2381699A1 CA 2381699 A1 CA2381699 A1 CA 2381699A1 CA 002381699 A CA002381699 A CA 002381699A CA 2381699 A CA2381699 A CA 2381699A CA 2381699 A1 CA2381699 A1 CA 2381699A1
Authority
CA
Canada
Prior art keywords
ests
angiogenesis
protein
nucleic acid
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002381699A
Other languages
English (en)
French (fr)
Inventor
Richard Murray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EOS Biotechnology Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2381699A1 publication Critical patent/CA2381699A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
CA002381699A 1999-08-11 2000-08-11 Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators Abandoned CA2381699A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14842599P 1999-08-11 1999-08-11
US60/148,425 1999-08-11
PCT/US2000/022061 WO2001011086A2 (en) 1999-08-11 2000-08-11 Methods of screening for angiogenesis modulators

Publications (1)

Publication Number Publication Date
CA2381699A1 true CA2381699A1 (en) 2001-02-15

Family

ID=22525710

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002381699A Abandoned CA2381699A1 (en) 1999-08-11 2000-08-11 Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators

Country Status (6)

Country Link
EP (1) EP1204764A2 (es)
JP (1) JP2003517816A (es)
AU (1) AU6902200A (es)
CA (1) CA2381699A1 (es)
MX (1) MXPA02001439A (es)
WO (1) WO2001011086A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803765B2 (en) 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
GB0002201D0 (en) * 2000-01-31 2000-03-22 Imperial College Process
US6855690B2 (en) 2000-06-01 2005-02-15 Children's Medical Center Corporation Methods and compositions for treating ocular disorders
JP2008001720A (ja) * 2002-06-21 2008-01-10 Japan Science & Technology Agency アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法
JP4393098B2 (ja) * 2002-06-21 2010-01-06 独立行政法人科学技術振興機構 アンサマイシン系抗生物質の新規用途及び新規血管新生抑制物質のスクリーニング方法
US7285268B2 (en) 2002-11-26 2007-10-23 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7276589B2 (en) 2002-11-26 2007-10-02 Pdl Biopharma, Inc. Chimeric and humanized antibodies to α5β1 integrin that modulate angiogenesis
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
US7485297B2 (en) 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
EP1721158A4 (en) * 2004-01-13 2008-07-30 Rigel Pharmaceuticals Inc MODULATORS OF ANGIOGENESIS
KR20070009637A (ko) 2004-03-24 2007-01-18 피디엘 바이오파르마 인코포레이티드 암 세포 증식을 억제하는 항α5β1 항체의 용도
WO2005119244A1 (en) 2004-06-03 2005-12-15 Phylogica Limited Peptide modulators of cellular phenotype and bi-nucleic acid fragment library
JP5576610B2 (ja) 2006-02-20 2014-08-20 フィロジカ リミテッド ペプチド構造のライブラリーの構築およびスクリーニング方法
BRPI0709338A2 (pt) 2006-03-21 2011-07-12 Genentech Inc anticorpo, molécula de ácido nucleico isolada, célula, composições, método de detecção da proteìna alfa5beta1, uso de anticorpo, métodos de tratamento, kit, uso de uma composição, uso de uma antagonista de alfa5beta e uso de uma antagonista de vegf
EP2074138A4 (en) 2006-09-19 2009-12-30 Phylogica Ltd NEUROPROTECTIVE PEPTIDE AP-1 SIGNALING INHIBITORS AND USES THEREOF
EP2170932A4 (en) 2007-06-20 2012-10-10 Phylogica Ltd COMPOSITIONS AND APPLICATIONS THEREOF IN THE TREATMENT OF ACUTE ATOMIC SYNDROME (ARDS) AND ASSOCIATED CLINICAL ILLNESSES
SI2200700T1 (sl) 2007-09-26 2016-04-29 Genentech, Inc. Nova protitelesa
MX2011010012A (es) 2009-03-25 2011-12-06 Genentech Inc NUEVOS ANTICUERPOS ANTI-A5ß1 Y SUS USOS.
SG10201601792UA (en) 2010-12-08 2016-04-28 Stemcentrx Inc Novel modulators and methods of use
JP2012125194A (ja) * 2010-12-16 2012-07-05 Mie Univ 腫瘍血管新生制御遺伝子
AU2014342610A1 (en) 2013-11-04 2016-06-02 Abbvie Stemcentrx Llc Anti-EFNA4 antibody-drug conjugates
US10883108B2 (en) 2016-03-31 2021-01-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1701814A (zh) * 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
WO1997034920A1 (en) * 1996-03-21 1997-09-25 Sugen, Inc. Assays for kdr/flk-1 receptor tyrosine kinase inhibitors
AU5340698A (en) * 1996-12-27 1998-07-31 Chugai Research Institute For Molecular Medicine, Inc. Novel serine-threonine kinase gene
AU7348998A (en) * 1997-05-16 1998-12-08 Hospital For Sick Children, The Inhibition of angiogenesis by verotoxins
WO1999011794A2 (en) * 1997-09-04 1999-03-11 Incyte Pharmaceuticals, Inc. New vrk1 kinase
EP1019080A2 (en) * 1997-10-02 2000-07-19 Leukosite, Inc. Modulation of lerk-2-mediated cell adhesion
JP2002501757A (ja) * 1998-01-29 2002-01-22 メルク エンド カムパニー インコーポレーテッド ストレス応答性キナーゼのモジュレーターの特定方法

Also Published As

Publication number Publication date
JP2003517816A (ja) 2003-06-03
WO2001011086A3 (en) 2002-03-07
MXPA02001439A (es) 2002-08-30
AU6902200A (en) 2001-03-05
WO2001011086A2 (en) 2001-02-15
EP1204764A2 (en) 2002-05-15
WO2001011086A9 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
US7736853B2 (en) Methods of diagnosis of androgen-dependent prostate cancer, prostate cancer undergoing androgen withdrawal, and androgen-independent prostate cancer
CA2381699A1 (en) Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators
US6682890B2 (en) Methods of diagnosing and determining prognosis of colorectal cancer
US20030235820A1 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
CA2438030A1 (en) Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
CA2453098A1 (en) Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
US6762020B1 (en) Methods of diagnosing breast cancer
US6750013B2 (en) Methods for detection and diagnosing of breast cancer
CA2451465A1 (en) Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
WO2000055633A9 (en) Methods of screening for colorectal cancer modulators
US6455668B1 (en) Methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US20030077590A1 (en) Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
US20020068036A1 (en) Novel methods of diagnosis of prostate cancer and/or breast cancer, compositions, and methods of screening for prostate cancer and /or breast cancer modulators
US20030108926A1 (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
US6649342B1 (en) Methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
US20020076707A1 (en) Novel methods of diagnosing cancer, compositions, and methods of screening for cancer modulators
US6566502B1 (en) Methods of diagnosing cancer, compositions, and methods of screening for cancer modulators
US20030157544A1 (en) Novel methods of diagnosing breast cancer, compositions, and methods of screening for breast cancer modulators
WO2002016939A2 (en) Methods of diagnosis of cancer and screening for cancer modulators
US20030044803A1 (en) Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US20030198951A1 (en) Novel methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
WO2002059609A2 (en) Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
WO2003027321A2 (en) Methods for diagnosis and treatment of diseases associated with altered expression of neurogranin
US20020102544A1 (en) Novel methods of diagnosing colorectal cancer, compositions, and methods of screening for colorectal cancer modulators
WO2002021134A2 (en) Methods of diagnosing breast cancer and screening for modulators

Legal Events

Date Code Title Description
FZDE Dead